PRKAA1抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using PRKAA1 mouse mAb against Jurkat (1), Hela (2), HepG2 (3), MCF-7 (4), Cos7 (5), NIH/3T3 (6), K562 (7), HEK293 (8), and PC-12 (9) cell lysate.    

  
  

•  

   

     Western blot analysis using PRKAA1 mouse mAb against COS7(1),C2C12(2),NIH/3T3(3) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of NTERA-2 cells using PRKAA1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of PC-2 cells using PRKAA1 mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer (left) and brain tissues (right) using PRKAA1 mouse mAb with DAB staining.    

  
  

The PRKAA1 antibody is a crucial tool for studying the alpha-1 catalytic subunit of AMP-activated protein kinase (AMPK), a highly conserved energy sensor central to cellular metabolism. AMPK, a heterotrimeric enzyme, regulates energy homeostasis by responding to fluctuations in ATP levels. PRKAA1 (also known as AMPKα1) forms the catalytic core alongside PRKAA2 (AMPKα2), with both isoforms displaying tissue-specific expression. PRKAA1 is ubiquitously expressed but particularly abundant in the liver, pancreas, and immune cells.

Researchers use PRKAA1 antibodies to investigate AMPK's role in metabolic pathways, including glucose uptake, lipid metabolism, and mitochondrial biogenesis. These antibodies enable detection of endogenous PRKAA1 protein levels in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specific antibodies targeting phosphorylated forms (e.g., at Thr172) help assess AMPK activation status under conditions like nutrient deprivation, exercise, or pharmacological stimulation.

Validated PRKAA1 antibodies are essential for studies linking AMPK dysfunction to metabolic disorders (e.g., diabetes, obesity), cancer progression, and neurodegenerative diseases. Commercial antibodies are typically raised against unique peptide sequences in human PRKAA1. with rigorous validation using knockout controls or siRNA-mediated silencing to confirm specificity. Proper antibody selection depends on experimental needs, as some recognize total PRKAA1 while others target post-translational modifications critical for functional studies.